5D5 Antibody Binding to CSP Cleavage Site
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preventing and treating malaria are inadequate in effectively targeting the proteolytic processing of Plasmodium sporozoites, which is conserved across various Plasmodium species, leading to challenges in developing broad-spectrum interventions.
Innovation Solution
Development of antibodies, such as the 5D5 antibody, that bind to an epitope in close proximity to the protease cleavage site of the circumsporozoite protein (CSP), preventing the invasion of Plasmodium sporozoites into the liver by inhibiting proteolytic processing, and their use in pharmaceutical compositions for prophylactic and therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If current methods for preventing and treating malaria are used, then existing treatments can address some Plasmodium species, but they fail to effectively target the conserved proteolytic processing across all Plasmodium species
Solution Approach 1:
The antibody 5D5 is designed to bind to a conserved epitope in the N-terminal domain of circumsporozoite protein that is present across all human-infecting Plasmodium species. This universal binding capability allows a single antibody to function against multiple Plasmodium species (P. falciparum, P. vivax, P. ovale, P. malariae), achieving broad-spectrum effectiveness while maintaining reliable inhibition of proteolytic processing at the conserved cleavage site
Solution Approach 2:
The invention targets a specific local region (the N-terminal domain containing the conserved cleavage site) of the circumsporozoite protein that is critical for proteolytic processing. By focusing the antibody binding site on this specific local quality that is conserved across all species, the invention achieves both broad-spectrum coverage and reliable inhibition of the essential proteolytic step required for liver invasion
2Reliability
If antibodies are developed to target the protease cleavage site of CSP, then liver invasion by sporozoites can be prevented, but the complexity of identifying and targeting the conserved epitope increases
Solution Approach 1:
The invention employs a preliminary action by first identifying and characterizing the conserved epitope in the N-terminal domain of circumsporozoite protein across multiple Plasmodium species before developing the antibody. This preliminary characterization of the conserved cleavage site and surrounding sequence allows for rational antibody design that targets the essential proteolytic processing step, thereby preventing liver invasion while managing the complexity through structured epitope identification
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The 5D5 antibodies significantly reduce or prevent the liver invasion of Plasmodium sporozoites, offering a broad-spectrum solution effective against all Plasmodium species infecting humans, as the cleavage site is conserved among them, thereby providing an effective prophylactic and therapeutic option for malaria.
Implementation Method 1
Development of antibodies, such as the 5D5 antibody, that bind to an epitope in close proximity to the protease cleavage site of the circumsporozoite protein (CSP)
Implementation Method 2
preventing the invasion of Plasmodium sporozoites into the liver by inhibiting proteolytic processing
Data Source
AI summary
This disclosure provides antibodies that are useful for preventing and/or treating malaria. The epitope to which the antibodies bind is in close proximity to the conserved proteolytic cleavage site of P. falciparum circumsporozoite protein (CSP), and the antibodies provided in this disclosure can prevent cleavage and inhibit P. falciparum sporozoites from invading the liver.